'Slow-Growth' Global Trend Shakes Up P&G Product Strategy Start To Finish
This article was originally published in The Pink Sheet
Executive Summary
P&G’s health care segment advanced 4% in the third quarter to $1.84bn, but sales declined for its other business units, a trend the firm sees worldwide across consumer industries. CFO Jon Moeller unveils the firm’s “irresistible superiority” product development strategy to counter slower global consumer spending.
You may also be interested in...
Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump
J&J says Tylenol outpaced other analgesics in the first quarter as its OTC franchise grew 1.4% on a reported basis to $1.01 bn. CFO Dominic Caruso said new consumer products will add 2 points of incremental growth to the segment in 2017.
P&G Portfolio Rationalization Brushes Off 20% Of Oral Care SKUs
P&G completes the bulk of the portfolio rationalization it launched in 2014, shedding or restructuring more than half of its brands globally to focus on 10 core categories, says CFO Jon Moeller.
Manufacturing, Advertising Coalition Tackles Digital Ad-Block Devastation
P&G and Unilever work with Google and advertising experts worldwide to form the Coalition for Better Ads aiming for new online advertising standards. The coalition has not yet determined whether Google would provide better placement for ads complying with the standards.